Document Detail


Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial.
MedLine Citation:
PMID:  15641045     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Gout affects a large fraction of persons with advanced chronic kidney disease, and hyperuricemia may increase the risk of cardiovascular disease. Several hypouricemic agents are contraindicated in patients with end-stage renal disease. Sevelamer is a nonabsorbed hydrogel that binds phosphorus and bile acids in the intestinal tract. Results of short-term and open-label studies suggest that sevelamer might lower the concentration of uric acid, another organic anion. We undertook this study to test our hypothesis that the reduction in serum uric acid concentration induced by sevelamer would be confirmed in a long-term, randomized, clinical trial comparing sevelamer with calcium-based phosphate binders. METHODS: Two hundred subjects undergoing maintenance hemodialysis were randomly assigned to receive either sevelamer or calcium-based phosphorus binders in an international, multicenter, clinical trial. Data on baseline and end-of-study uric acid concentrations were available in 169 subjects (85%); the change in uric acid concentration from baseline to the end of the study was the outcome of interest. RESULTS: Baseline clinical characteristics, including mean uric acid concentrations, were similar in subjects randomly assigned to receive sevelamer and calcium-based phosphate binders. The mean change in uric acid concentration (from baseline to the end of the study) was significantly larger in sevelamer-treated subjects (-0.64 mg/dl versus -0.26 mg/dl; P = 0.03). The adjusted mean change in uric acid concentration was more pronounced when the effects of age, sex, diabetes, vintage (time since initiation of dialysis), dialysis dose, and changes in blood urea nitrogen and bicarbonate concentrations were considered (-0.72 mg/dl versus -0.15 mg/dl; P = 0.001). Twenty-three percent of sevelamer-treated subjects experienced a study-related reduction in the concentration of uric acid equal to -1.5 mg/dl or more, compared with 10% of calcium-treated subjects (P = 0.02). CONCLUSION: In a randomized clinical trial comparing sevelamer and calcium-based phosphate binders, treatment with sevelamer was associated with a significant reduction in serum uric acid concentrations.
Authors:
Jay P Garg; Scott Chasan-Taber; Andrew Blair; Melissa Plone; Juergen Bommer; Paolo Raggi; Glenn M Chertow
Related Documents :
3247355 - Effects of trema guineense decoction on some metabolic activities in the rat.
7176335 - Pathogenesis and clinical course of mixed calcium oxalate and uric acid nephrolithiasis.
2500615 - Uric acid and its relationship with glycosaminoglycans in normal and stone-former subje...
20123605 - Association of perfluorooctanoic acid (pfoa) and perfluorooctane sulfonate (pfos) with ...
7943335 - Secretin: a physiological regulator of gastric emptying and acid output in dogs.
1744535 - Effects of folia orthosiphonis on urinary stone promoters and inhibitors.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Arthritis and rheumatism     Volume:  52     ISSN:  0004-3591     ISO Abbreviation:  Arthritis Rheum.     Publication Date:  2005 Jan 
Date Detail:
Created Date:  2005-01-13     Completed Date:  2005-02-15     Revised Date:  2005-11-17    
Medline Journal Info:
Nlm Unique ID:  0370605     Medline TA:  Arthritis Rheum     Country:  United States    
Other Details:
Languages:  eng     Pagination:  290-5     Citation Subset:  AIM; IM    
Affiliation:
Department of Medicine Research, University of California-San Francisco, UCSF Laurel Heights Suite 430, 3333 California Street, San Francisco, CA 94118-1211, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Biological Markers / blood
Calcium
Epoxy Compounds / therapeutic use*
Female
Humans
Kidney Failure, Chronic / blood*,  drug therapy,  therapy*
Male
Middle Aged
Multivariate Analysis
Osmolar Concentration
Phosphate-Binding Proteins / chemistry,  therapeutic use*
Polyamines
Polyethylenes / therapeutic use*
Renal Dialysis*
Uric Acid / antagonists & inhibitors,  blood*
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Epoxy Compounds; 0/Phosphate-Binding Proteins; 0/Polyamines; 0/Polyethylenes; 182683-00-7/sevelamer; 69-93-2/Uric Acid; 7440-70-2/Calcium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Serum hyaluronan levels and radiographic knee and hip osteoarthritis in African Americans and Caucas...
Next Document:  C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthri...